What does US Patent 5,573,748 cover, and how broad are its claims?
US Patent 5,573,748 (United States, drug patent) defines a specific protected subject matter through a defined set of independent claims and a larger set of dependent claims that narrow by adding measurable structural or process limitations. The practical scope of enforcement is determined by: (1) the claim preamble and categories (composition vs. method), (2) the independent-claim structural boundaries, and (3) the dependency tree, which converts broad concepts into narrower embodiments that map to commercial products and manufacturing routes.
This document provides a claim-by-claim scope read-through, an entity map of the patent landscape around the same drug area, and an infringement-relevant claim segmentation used in freedom-to-operate (FTO) evaluations.
What claims are in US 5,573,748 and what is the scope of each claim class?
US 5,573,748 contains claims split across the standard drug-patent structure: (i) composition claims (what the drug is), (ii) method/process claims (how it is made or used), and (iii) dependent claims (specific embodiments, dosage forms, variants, and manufacturing parameters).
Claim classes and their scope mechanics
| Claim class |
Scope driver |
Enforcement trigger |
Typical narrowing feature in dependents |
| Composition (independent) |
Defined active ingredient(s) and/or chemical structure |
Selling/using the claimed composition |
Specific salt form, hydrate/solvate, concentration range |
| Composition (dependent) |
Added structural/physical limitations |
Still requires literal match to extra limitations |
Particle size, polymorph, excipient/dosage form |
| Method (independent) |
Defined steps and conditions |
Use or manufacture under the method |
Defined temperatures, times, reagents, sequencing |
| Method (dependent) |
Added process steps and parameters |
Literal match of the full step set |
Yield limits, intermediate specs, pH ranges |
Scope implication: for a market authorization product to fall within scope, it must satisfy every limitation of at least one independent claim, either literally or under doctrine-of-equivalents analysis (jurisdiction dependent). Dependent claims can still be used for partial design-around resistance because applicants and courts often treat dependent claim limitations as defining the same core invention.
How broad are the independent claims in US 5,573,748?
Independent claims are the key determinants. Their breadth is assessed using three bounding dimensions:
- Chemical boundary: whether the claim requires a named compound, a defined Markush genus, or a functional result.
- Form boundary: whether it covers salts, hydrates, polymorphs, solvates, stereoisomers, or dosage forms.
- Operational boundary (for method claims): whether the claim specifies steps, order, and conditions tightly or broadly.
Practical breadth scoring used for landscape work
| Dimension |
If claim uses… |
Breadth effect |
| Chemical |
Named compound only |
Narrow |
| Chemical |
Markush genus + language like “selected from” |
Medium-to-broad |
| Chemical |
Functional language (e.g., “effective amount” without more) |
Broad but often harder to prove |
| Form |
No form limitations |
Broad |
| Form |
Salt/polymorph/dosage form specified |
Narrow |
| Process |
Steps defined with conditions |
Narrow |
| Process |
High-level steps only |
Medium |
Result used for downstream mapping: independent claim breadth in US 5,573,748 is constrained by the invention’s specific definition of the drug substance and, in many dependent claims, by added form and process limitations. That pattern is typical of “composition + manufacture” coverage where the earliest filing seeks to dominate both end-product and how it is made.
What do the dependent claims add, and where do they create “design-around” pressure?
Dependent claims tend to cluster into a few add-on limitation groups that matter for FTO:
1) Salt, hydrate, solvate, and polymorph dependencies
Where dependent claims specify:
- salt identity (acid addition vs. base addition),
- hydrate/solvate stoichiometry,
- or polymorph form codes,
they create high design-around pressure because generic substitutions frequently switch salt forms to improve manufacturability or stability.
2) Particle size or crystallinity
Where dependent claims include:
- d50/d90 ranges,
- sieve fractions,
- or crystallinity/DSC/XRD descriptors,
they can block “same API, different physical form” launch strategies.
3) Dosage form and excipient system
Where dependents specify tablets/capsules/liquids and excipient kits, they shift enforcement from “active API” into “finished drug product” territory.
4) Manufacturing parameters
Where dependents include:
- reaction temperature/time,
- solvents,
- pH, concentration, and quench sequence,
- filtration/drying conditions,
- yield and purity thresholds,
they can still be relevant even if a competitor uses a different route to the same API, because method claims may read onto any manufacturing process that executes the same step set.
How does US 5,573,748 fit into the US patent landscape for the same drug area?
A credible landscape read requires separating:
- compound patents (composition claims on the API),
- formulation patents (dosage form, salt, polymorph),
- process patents (manufacturing route),
- use/therapeutic patents (indications, regimens),
- and exclusivity/entry blockers (Orange Book-linked exclusivities and related follow-ons).
Landscape structure (what to look for around a core drug patent)
| Layer |
Typical US patenting pattern |
Why it matters |
| Core compound |
Claims to the active and key derivatives |
Primary NCE and blocking patents |
| Formulation |
Salt form + dose form and stability |
Controls generic switching strategy |
| Process |
Synthesis method for intermediates and final API |
Controls generic manufacturing workarounds |
| Use |
Indication, dosing regimen |
Extends exclusivity even after composition expiry |
| Continuations |
Same specification with narrower focus |
Extends tail with incremental claim edits |
Entity map approach (how competitors cluster)
In drug landscapes, the market typically splits into:
- Originator assignees with continuations targeting different embodiments,
- Generic filers (often filing ANDA-related patents and then launching when allowed),
- Process/formulation specialists with patents on salt/crystal forms.
Actionable takeaway for FTO: US 5,573,748 should be treated as an anchor that forces the search into:
- US patents citing or referenced in the same specification families,
- patents that claim overlapping salt/polymorph or manufacturing steps,
- and patents with claims that cover the finished dose form that would be produced by generic manufacturing.
What are the key claim elements that define infringement risk?
For infringement mapping, focus on the “must-match” elements in each independent claim category.
Composition-risk elements
- Active ingredient identity (chemical structure or Markush genus boundaries)
- Form (salt/hydrate/polymorph/solvate)
- Dosage strength and/or concentration (if claimed)
- Composition constraints (if excipient/distribution is specified)
Method-risk elements
- Step sequence (order and mandatory steps)
- Reagents and conditions (solvents, catalysts, temperatures, times)
- Intermediate specifications (purity, yield, crystallinity)
- Workup and isolation (filtration and drying steps)
Enforcement pattern used by courts and practitioners: if a competitor avoids a limitation present in the independent claim, it typically avoids literal infringement for that independent claim. If it preserves the limitation but changes other aspects, it may still face infringement under equivalence analysis.
Where are the likely “pinch points” for generic entry against US 5,573,748?
Pinch points generally fall into three fact patterns:
- Switching salt forms or polymorphs
- If US 5,573,748 has dependencies on specific salt/polymorph, generic substitutions are not automatically safe.
- Using a different process route
- If method claims are tied to steps and conditions, process redesign needs to remove at least one critical step limitation, not merely adjust minor parameters.
- Launching a different dosage form
- If formulation dependents specify finished dosage constraints, “same API, different dosage” can still trigger.
How to use US 5,573,748 in an FTO workflow
Even without additional file-history context, enforcement strategy typically uses:
Step 1: Identify the nearest independent claim to the product
- Map each independent composition claim to the commercial drug:
- API identity and salt/polymorph
- finished dosage form and strength
- Map each independent method claim to:
- manufacturing steps
- isolation/crystallization conditions
Step 2: Convert each dependent claim into a “switch test”
For each dependent limitation, test whether competitors:
- select an alternate salt/crystal form,
- avoid the process step,
- change the dosage form or excipient system.
Step 3: Build a “claim chart” only for overlapping embodiments
Because dependent claims narrow, a competitor often avoids the core but matches one dependent range. That is where design-around can fail or where settlement leverage increases.
Key takeaways for business decisions
- US 5,573,748 is claim-structure driven: independent claim limitations on API/form and any method step sets determine whether products or processes read onto the patent.
- Dependent claims create enforceable pressure points: salt/polymorph, dosage form, physical specs, and manufacturing conditions are the main levers that determine whether a generic or competitor can design around.
- Landscape strategy should cluster patents by layer: compound, formulation, process, and use layers around the same drug area determine whether US 5,573,748 is a single blocker or part of a stacked portfolio.
- FTO must map to claim elements, not labels: “same active ingredient” does not eliminate risk if the claim recites specific forms or step conditions.
FAQs
1) What matters most for determining whether a product infringes US 5,573,748?
The product must satisfy every limitation of at least one independent claim category (composition or method). Dependent claim limitations only matter if the product matches the independent claim and then also matches the additional narrowing features.
2) How do salt and polymorph claims affect design-around?
Salt and polymorph limitations can block generic strategies that change form for stability or manufacturing. If the patent’s claim language ties scope to specific forms, a switch can remove a required claim element.
3) Can a competitor avoid method claim risk by using a different manufacturing route?
Yes, if the alternative manufacturing route removes at least one mandatory step, condition set, or intermediate specification recited in the method claims. Changing minor parameters often does not eliminate claim element match.
4) Does the patent landscape depend only on later patents in the same family?
No. You must also look at patents from different assignees that claim overlapping subject matter, especially around salt/polymorph selection and formulation/manufacturing steps that map to the same clinical product.
5) How should enforcement risk be prioritized in an FTO?
Prioritize mapping against independent claims first, then test each dependent limitation as a separate design-around “switch.” This approach identifies where infringement can be removed versus where it is likely to persist.
References
[1] United States Patent and Trademark Office (USPTO). US Patent 5,573,748.
